Marker for identifying and diagnosing latent tuberculosis infection and active tuberculosis, and use thereof

By detecting the expression of CCL8, CXCL9 and CCL19 after peripheral blood mononuclear cells are stimulated, the problem that the prior art cannot distinguish between latent tuberculosis infection and active tuberculosis is solved, and the sensitivity and accuracy of diagnosis are improved.

WO2024239382A1PCT designated stage expired Publication Date: 2024-11-28BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1

Patent Information

Application Number
PCT/CN2023/098737
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-23
Filing Date
2023-06-07
Publication Date
2024-11-28

Smart Images

  • Figure CN2023098737_28112024_PF_FP_ABST
    Figure CN2023098737_28112024_PF_FP_ABST
Patent Text Reader

Abstract

A biomarker for identifying and diagnosing latent infection and active tuberculosis, and the use thereof. The biomarker is one or more of CCL8, CXCL9 and CCL19. When the expression level of one or more of CCL8, CXCL9 and CCL19 is respectively higher than a critical value of the marker, the subject can be diagnosed with active tuberculosis; and when the expression level of one or more of CCL8, CXCL9 and CCL19 is respectively lower than or equal to the critical value of the marker, the subject can be diagnosed with latent tuberculosis infection. The biomarkers have the advantages of high sensitivity and specificity, high diagnosis efficiency, and simple and convenient operation, and can improve the diagnosis efficiency of latent infection and active tuberculosis.
Need to check novelty before this filing date? Find Prior Art

Description

A marker for differential diagnosis of latent tuberculosis infection and active tuberculosis and its application Technical Field

[0001] The present invention relates to the field of medical technology, and relates to a marker for differential diagnosis of latent tuberculosis infection and active tuberculosis and application thereof. Background Art

[0002] Tuberculosis (TB) is a major public health challenge worldwide. Mycobacterium tuberculosis (MTB) primarily invades the human body through the respiratory tract, causing active TB in a minority of cases, while the majority remain latent. Latent TB infection (LTBI) refers to a state in which the body maintains a persistent immune response to MTB antigens, but lacks clinical evidence of active TB. The World Health Organization estimates that approximately a quarter of the global population is infected with TB, and approximately 5% to 10% of those with LTBI will develop active TB. LTBI is a significant source of active TB and a key focus of TB prevention and control. To achieve the WHO's goal of ending TB by 2035, early detection and diagnosis of LTBI are crucial.

[0003] Mycobacterium tuberculosis is an intracellular, aerobic pathogen that typically enters the body through the respiratory tract and then spreads to other sites via the lymphatic vessels or blood. Lymphocytes and macrophages flow en masse to the site of infection, forming granulomas. Within these macrophages, the bacteria continue to grow until the macrophages die, at which point the bacteria are released back into the infected lesion. During this process, M. tuberculosis interacts with the body's immune cells primarily through innate and acquired immune responses, with three common outcomes: clearance of the bacterium by the innate immune system; proliferation of M. tuberculosis within the host, leading to active tuberculosis (ATB); or the bacterium persists in a quiescent state within granulomas and macrophages, where it is controlled by the host immune response but not eliminated, resulting in latent tuberculosis infection (LTBI). Conservative estimates suggest that approximately one-third of the world's population, or approximately 2 billion people, have latent tuberculosis infection, and the lifetime risk of developing active TB in these patients is 5-10%.

[0004] Currently, the main tuberculosis screening tests and methods for diagnosing LTBI include the tuberculin skin test (TST) and the interferon-γ release assay (IGRA). The TST is simple to perform, low-cost, and widely used in my country; however, its complex antigen composition is susceptible to factors such as BCG vaccination, non-tuberculous mycobacterial infection, and immune status, resulting in low sensitivity and specificity. The IGRA has improved sensitivity and specificity compared to the TST. However, in addition to its limited widespread use due to cost-effectiveness, its major drawback is that it still cannot distinguish between LTBI and active TB. Furthermore, in patients with HIV and TB, insufficient interferon-γ release may occur, affecting the interpretation of the results. Therefore, the search for biomarkers other than IFN-γ is urgently needed in clinical practice.

[0005] Current adjunct diagnostics also include radiologic imaging, which provides guidance regarding the presence or absence of typical features, and IGRA and TST, which provide information about possible prior exposure to M. tuberculosis by querying immune responses to TB-associated antigens. The interpretation of IGRA and TST tests is complex and confounded by many factors. These include several: prior exposure (latent disease), prior BCG or other vaccinations, and immunosuppression. Unfortunately, imaging, TST, and IGRA tests cannot definitively diagnose or exclude the presence of active disease, and no currently available test can identify or exclude the presence of extrapulmonary TB.

[0006] Studies have shown that when peripheral blood mononuclear cells are stimulated by tuberculosis-specific antigens, they release various inflammatory markers. The release of these inflammatory markers is associated with the body's immune response against tuberculosis infection, ultimately leading to the different outcomes of active tuberculosis and latent infection. Therefore, certain inflammatory markers may be unique to active tuberculosis and latent infection. With the development of Luminex suspension chip technology, multiple biomarkers can be detected and screened simultaneously. The differentially expressed inflammatory factors obtained can serve as markers to distinguish active tuberculosis from latent infection, providing a reference for the clinical diagnosis and treatment of tuberculosis.

[0007] Recently publications have emphasized the potentiality of using the combination of biomarkers as the diagnostic tool of tuberculosis.WO03 / 075016 describes detectable soluble protein levels in blood, i.e. soluble CD antigens (" sCD ") sCD15sCD23, sCD27 and sCD54, which may be changed in tuberculosis patients. The Medscape Medical News article from the American Thoracic Society (AmericanThoracic Society, ATS) 2010 international conference shows that the combination of IL-15 and MCP-1 accurately classifies 84% ​​patients as having active or latent tuberculosis. Chegou (the second IGRA global conference (2Global Symposium on IGRAs), 2009 May-June) has described and compared single analyte, and analyte combination is more promising TB diagnostics and proposes to measure EGF, sCD40L, MIP-1B, VEGF, TGF-α or IL-1a as the rapid test of active TB. Wu et al. (2007) J mmunol 178 3688-3694 indicate that IL-8 FOXP3 and IL-12B provide a means of distinguishing latent Mycobacterium tuberculosis infection from active tuberculosis disease.

[0008] Because current TB diagnostic methodologies are suboptimal, there are too many treatment options available for the disease. As a result of the intracellular nature of the pathogen and the lack of sufficient innovation in the field of TB therapeutics, the basis of TB treatment remains, in the simplest case, combined antimicrobial chemotherapy over an extended period of several months. However, partial compliance with treatment can lead to suboptimal therapeutic levels of antimicrobials and subtle evolution of antibiotic-resistant mutations. As a result, patients may remain infectious for a longer period of time, increasing the frequency of transmission. The development of these resistance mutations, some of which are unresponsive to all known anti-TB drugs (multidrug resistance), has recently attracted great attention in India. Therefore, there is a great need to identify more effective and efficient methods for simultaneously confirming active and latent TB, and in particular for the differential diagnosis of active and latent TB.

[0009] Patent CN113748342A discloses the use of a panel of biomarkers IFNγ, IL-10, CD120b, and CD14 for diagnosing active mycobacterial infection and / or monitoring the progression of active mycobacterial infection, or for diagnosing the absence of mycobacterial infection, in particular tuberculosis.

[0010] CN104459129A provides a diagnostic kit for distinguishing active Mycobacterium tuberculosis infection from latent Mycobacterium tuberculosis infection using cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) as a diagnostic marker, and a method for distinguishing active and latent Mycobacterium tuberculosis infection using the diagnostic kit. The diagnostic kit includes CTLA-4, CD3, CD4, CD25, FoxP3 fluorescent antibodies, etc. The present invention is used to detect the expression level of CTLA-4 in the patient's peripheral venous blood, which can be used for the differential diagnosis of active Mycobacterium tuberculosis infection from latent infection with high sensitivity and accuracy, providing a strong basis for clinical differential diagnosis.

[0011] Chemokines are a family of highly conserved proteins (relative molecular mass 8000-12000) that participate in many biological processes, including chemotactic cell migration, immune cell degranulation, hematopoiesis, and angiogenesis (Miller MC, Mayo KH. Chemokines from a Structural Perspective. Int J Mol Sci, 2017, 18(10): 2088. doi: 10.3390 / iims18102088.). Chemokines are generally divided into three subfamilies based on the sequential positioning of their highly conserved cysteine ​​residues: CC motif (CC) chemokines, CXC motif (CXC) chemokines, and C-X3-C motif (CX3C) chemokines. The biological functions of chemokines are mostly classified as inflammatory factors. They play a key role in controlling the recruitment of immune cells in inflammatory reactions, that is, chemokines play an important role in organizing immune responses (Zlotnik A, Yoshie O. The chemokine superfamily revisited Immunit, 2012, 36(5): 705-716 doi: 10.1016 / j.immuni.2012.05.008.). Li Youlun et al. believe that chemokines bind to receptors on their corresponding target cells in the human body and activate corresponding signaling pathways by inducing the dissociation of the BY subunit of the G protein to exert their biological functions. Different types of chemokines have different functions. CC chemokines mainly chemotactic monocytes, CXC chemokines mainly chemotactic neutrophils, C chemokines can chemotactic lymphocytes, and the CX3C subfamily is mainly involved in the migration and activation of giant cells and lymphocytes. In addition, chemokines play a role in the MTB infection process, being crucial for recruiting and coordinating the entry of immune cells into the MTB-infected lungs. Monocyte recruitment and localization can effectively control bacterial growth and prevent the development of diffuse granulocytic inflammation. For example, interferon-induced protein 10 (IP-10 / CXCL10) can mediate the migration and activation of immune cells in the human body by binding to receptors on target cells, playing a crucial role in anti-TB immunity. However, certain chemokines and cytokines exacerbate the spread of infection and tissue damage, exerting a dual effect on the anti-MTB infection process. Under certain conditions, chemokines can also cause disproportionate inflammation and lung damage, thereby accelerating the progression of lung disease and cavitation.

[0012] Summary of the Invention

[0013] In response to the current technical limitations in distinguishing and detecting biomarkers of latent tuberculosis infection and active tuberculosis, the present invention extracts chemokines secreted by peripheral blood mononuclear cells after being stimulated with tuberculosis-specific antigens, and uses high-throughput Luminex suspension chip technology to screen biomarkers of latent tuberculosis infection and active tuberculosis, which can effectively improve diagnostic sensitivity and reduce false negative diagnoses.

[0014] In a first aspect, the present invention provides a biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis, wherein the marker is one or more of CCL8, CXCL9 and CCL19. When the expression levels of one or more of CCL8, CXCL9 and CCL19 are respectively higher than the critical value of the factor, the patient can be diagnosed as a patient with active tuberculosis; when the expression levels of one or more of CCL8, CXCL9 and CCL19 are respectively lower than or equal to the critical value of the factor, the patient can be diagnosed as having latent tuberculosis infection.

[0015] Furthermore, the critical values ​​(pg / mL) of the expression levels of CCL8, CXCL9 and CCL19 were 397.46, 1361.44 and 287.07, respectively.

[0016] Furthermore, the tuberculosis is an infectious disease caused by the presence of the pathogen Mycobacterium tuberculosis.

[0017] Furthermore, the Mycobacterium tuberculosis infection includes: primary infection, secondary infection, and extrapulmonary infection.

[0018] Furthermore, the tuberculosis includes but is not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

[0019] Furthermore, the drug-resistant tuberculosis includes but is not limited to monodrug-resistant tuberculosis, multidrug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.

[0020] Furthermore, the pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, negative pulmonary tuberculosis, etc.

[0021] Furthermore, the extrapulmonary tuberculosis includes but is not limited to intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.

[0022] In a second aspect, the present invention provides a kit for differential diagnosis of latent tuberculosis infection and active tuberculosis, wherein the kit contains reagents for detecting biomarkers, instructions, etc., and the markers are one or more of CCL8, CXCL9, and CCL19.

[0023] In a third aspect, the present invention provides a use of a biomarker in preparing a preparation for differential diagnosis of latent infection and active tuberculosis.

[0024] Furthermore, the biomarkers are one or more of CCL8, CXCL9 and CCL19.

[0025] Furthermore, when one or more of CCL8, CXCL9 and CCL19 are respectively higher than the critical value of the factor, the patient can be differentially diagnosed as a patient with active tuberculosis; when one or more of CCL8, CXCL9 and CCL19 are respectively lower than or equal to the critical value of the factor, the patient can be differentially diagnosed as a patient with latent infection.

[0026] Furthermore, the critical values ​​(pg / mL) of CCL8, CXCL9 and CCL19 were 397.46, 1361.44 and 287.07, respectively. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 shows the chemokine expression levels of peripheral blood mononuclear cells from healthy controls (HC), latently infected individuals (LTBI), and IGRA-positive tuberculosis patients (TB IGRA+) after stimulation with tuberculosis antigens.

[0028] FIG2 is a ROC curve analysis diagram of MCP-2 / CCL8.

[0029] FIG3 is a ROC curve analysis diagram of MIG / CXCL9.

[0030] FIG4 is a ROC curve analysis diagram of MIP-3β / CCL19.

[0031] FIG5 is a graph showing ROC curve analysis of MIG / CXCL9 and MCP-2 / CCL8 combinations. DETAILED DESCRIPTION

[0032] The following is a further description of specific embodiments of the present invention. It should be noted that the description of these embodiments is intended to facilitate understanding of the present invention and does not constitute a limitation of the present invention. In addition, the technical features involved in the various embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.

[0033] The experimental methods in the following examples are conventional methods unless otherwise specified, and the experimental materials used in the following examples are commercially available unless otherwise specified.

[0034] The "CCL8" mentioned in this article, also known as monocyte chemoattractant protein-2 (MCP-2), is a key member of the CC family of chemokines. It plays a crucial role in B cell and mitochondrial maturation and T cell differentiation, participating in both Th1 and Th2 immune responses. Therefore, CCL8 plays a crucial immunomodulatory role in inflammatory responses, immune responses, and tumor immunity. Chemokines are a large class of low molecular weight proteins with highly homologous three-dimensional structures. They were originally discovered for their role in guiding leukocyte migration and proliferation. The chemokine family has 27 members, of which chemokines are a subfamily and are a crucial component of intercellular communication. Chemokines can produce biological effects by binding to seven-transmembrane G protein-coupled receptors (GPCRs). Chemokines are generally divided into four families based on the configuration of their N-terminal cysteine ​​residues: CC, CXC, CX3C, and XC. CCL8 is a member of the CC chemokine family, and its encoding gene is one of several chemokine genes clustered on the q arm of chromosome 17. CCL8 participates in immune regulation and inflammatory responses. Its structure is essentially identical to other members of the CC chemokine family, sharing a common structural characteristic of the CC family: two vicinal disulfide bonds formed by four cysteine ​​residues within its amino acid structure. The CCL8 precursor protein consists of 109 amino acids, while the mature CCL8 protein consists of 75 amino acids.

[0035] The "CXCL9" mentioned in this article is the chemokine monokine induced by interferon-γ (MIG), which belongs to the CXC family of chemokines. It is mainly produced by macrophages stimulated by IFN-γ in the body. Its structural characteristics are a precursor protein sequence with 125 amino acids and a signal peptide sequence containing 21 amino acids. Compared with other chemokines, it contains more than 50% basic amino acids, so its molecular weight is larger than most other chemokines. The hydroxyl end of CXCL9 is easily hydrolyzed and broken, resulting in a certain difference in the size of natural and recombinant CXCL9. CXCL9 plays a key role in leukocyte trafficking and acts on activated CD4 + Th1 cells, CD8 + T cells, IL-2 activated T lymphocytes and NK cells. After the receptor CXCR3 is activated, it can be rapidly induced to produce and in the Th1 type CD4 + T cells and effector CD8 +CXCL9 is highly expressed in T cells such as NK cells and NKT cells. Therefore, it plays an important role in many diseases, including external infections, tumor treatment, autoimmune diseases, and transplant rejection.

[0036] The chemokine CC-motif ligand 19 (CCL19) belongs to the CC chemokine family and is also known as EBI1 ligand chemokine (ELC) and macrophage inflammatory protein-3β (MIP-3β). CC cytokines are characterized by two adjacent cysteines. The CCL9 gene is located on human chromosome 9. CCL19 is abundantly expressed in the thymus and lymph nodes, with moderate expression in the trachea and colon, and lower levels in the stomach, small intestine, lung, kidney, and spleen. CCL19 specifically binds to the chemokine receptor CCR7, thereby inducing effects on its target cells. CCL19 may play a role in normal lymphocyte recirculation and homing, and may also play an important role in the migration of thymic T cells and T and B cells to secondary lymphoid organs.

[0037] In the present invention, MCP-2 and CCL8 have the same concept and can be interchanged; MIG and CXCL9 have the same concept and can be interchanged; MIP-3β and CCL19 have the same concept and can be interchanged.

[0038] "Tuberculosis" as referred to herein includes infectious diseases caused by the presence of the pathogen Mycobacterium tuberculosis. Reference to tuberculosis also includes reference to active symptomatic tuberculosis infection and latent asymptomatic tuberculosis infection (LTBI). Most instances of tuberculosis infection are primarily confined to the lungs (i.e., pulmonary tuberculosis), however, approximately a quarter of active tuberculosis infections metastasize from the lungs, causing other types of tuberculosis, collectively referred to as extrapulmonary tuberculosis.

[0039] In one embodiment, the active mycobacterial infection is tuberculosis.

[0040] As described in this article: Sensitivity = true positive value / (true positive value + false negative value); Specificity = true negative value / (true negative value + false positive value); Positive likelihood ratio = true positive value / (true positive value + false positive value); Negative likelihood ratio = true negative value / (true negative value + false negative value); Accuracy = (true positive value + true negative value) / (true positive value + true negative value + false negative value + false positive value); False positive refers to the result of misjudging a patient who does not have tuberculosis as a positive patient for various reasons, and false negative refers to misjudging a patient with tuberculosis as not having tuberculosis.

[0041] Example 1 Screening of Molecular Markers for Latent Infection and Active Tuberculosis

[0042] 1.1 Case collection

[0043] Samples were collected from three groups of subjects: healthy controls (HC), latently infected individuals (LTBI), and IGRA-positive tuberculosis patients (TB IGRA+). EGRA testing cannot distinguish between latently infected and TB patients. However, the screened chemokines or cells can effectively distinguish between these two groups, complementing the EGRA test.

[0044] The EGRA test results of tuberculosis patients are divided into two situations. One is positive, accounting for about 85%, and the other is: although the patient is a tuberculosis patient, the EGRA test result is negative.

[0045] 1.1.1 Active pulmonary tuberculosis refers to patients with clinical symptoms of tuberculosis, confirmed by sputum acid-fast bacilli smear or culture, and confirmed by pathology or sputum molecular biology;

[0046] 1.1.2 Inclusion criteria for latently infected patients: high risk factors for tuberculosis infection, positive tuberculosis-specific IGRA test, and no evidence of tuberculosis infection on chest radiograph;

[0047] 1.1.1 Healthy controls: no high-risk factors for tuberculosis infection and no obvious abnormalities on chest X-ray.

[0048] The above populations were excluded from patients with tumors, those taking immunomodulatory drugs, HIV infection and other autoimmune diseases.

[0049] 1.2 Stimulation of peripheral blood cells with Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10

[0050] 1.2.1 Sample Collection: 4 mL of peripheral blood was collected from each subject in the morning on an empty stomach and placed in a blood collection tube containing sodium heparin for anticoagulation. The blood was then added to a cell stimulation culture tube for stimulation culture within 6 hours of collection. The blood was not allowed to be frozen or centrifuged.

[0051] 1.2.2 Sample packaging: Gently mix the blood collection tube by inverting it upside down 8 times, draw 0.6 mL of fresh human venous anticoagulated blood from each tube, add it to the cell stimulation culture tube (N, T, P), and mix the culture tube by inverting it upside down 5 times.

[0052] 1.2.3 Culture: Place the cell stimulation culture tube in a constant temperature incubator at 37±0.5℃ for 20±2h. Keep the culture tube upright during the culture process.

[0053] 1.2.4 Separation: After incubation, the culture tubes can be centrifuged (1000 g, 5 min) or other methods to separate the plasma.

[0054] 1.3 Liquid suspension chip technology detection

[0055] This study used the Bio-Plex Pro Human Chemokine Panel 40-plex kit to detect chemokines in plasma stimulated with specific antigens from three groups of people: healthy controls, latently infected individuals, and IRGA-positive tuberculosis patients. The specific steps are as follows:

[0056] 1.3.1 Sample preparation

[0057] Cell culture plasma: Centrifuge at 10,000 rpm for 10 minutes, take the supernatant, dilute 4-fold with Sample Diluent, and finally take 50 μL of the diluted sample for detection.

[0058] 1.3.2 Preparation of Standards

[0059] Add 781 μL of Standard Diluent to the standard bottle, vortex for 5 seconds, and place on ice for 30 minutes. Dilute the standard in series according to the instructions.

[0060] 1.3.3 Sample incubation

[0061] (1) Oscillate the beads on an oscillator at 1400 rpm for 30 seconds and dilute the beads with Assay Buffer.

[0062] (2) The diluted beads were shaken again at 1400 rpm for 30 s, 50 μL per well was added to a 96-well plate, and washed three times using a plate washer;

[0063] (3) Take 50 μL of the prepared standard, sample, reference and Blank and add them to a 96-well plate. Cover with sealing film and place on a plate shaker at 850 rpm. Incubate at room temperature for 1 h in the dark.

[0064] 1.3.4 Incubation with detection antibodies

[0065] (1) Discard the sample and wash three times using a plate washer;

[0066] (2) Use Antibody Diluent to dilute the detection antibody according to the instructions;

[0067] (3) Add 25 μL of diluted Detection Antibody to each well, cover with sealing film, place on a plate shaker at 850 rpm, protect from light, and incubate at room temperature for 30 minutes.

[0068] 1.3.5 Color Rendering

[0069] (1) Discard the detection antibody and wash the plate three times using a plate washer;

[0070] (2) Dilute Streptavidin-PE using Assay Buffer according to the instructions;

[0071] (3) Add 50 μL of diluted Streptavidin-PE to each well, cover with sealing film, place on a plate shaker at 850 rpm, protect from light, incubate at room temperature for 10 min;

[0072] (4) Wash three times using a plate washer;

[0073] (5) Add 125 μL of Assay Buffer to each well to resuspend, cover with sealing film, and place on a plate shaker at 850 rpm at room temperature, protected from light, and shake for 30 seconds;

[0074] (6) The sample was sent to the calibrated BioPlex 200 machine for reading.

[0075] 1.4 Data Results

[0076] After the samples and standards are tested by the BioPlex 200 detector, the fluorescence obtained is automatically calculated and optimized by the software to form an Excel format output file.

[0077] 1.5 Screening biomarkers

[0078] Based on the expression levels of the 40 cytokines and chemokines detected in these three populations, chemokines with differential expression between latently infected individuals and healthy controls, and between latently infected individuals and tuberculosis patients were screened out. After stimulation with tuberculosis-specific antigens, the expression of MCP-2 / CCL8, MIG / CXCL9, and MIP-3β / CCL19 showed significant differences between latently infected individuals and healthy controls, as well as tuberculosis patients, and can be used as diagnostic biomarkers (see Figure 1).

[0079] The 40 cytokines and chemokines are as follows:

[0080] CCL21, CXCL13, CCL27, CXCL5, CCL24, CCL26, CCL11, CX3CL1, CXCL6, GMCSF, CXCL1, CXCL2, CCL1, CXCL11, IFN-r, IL-1B, IL-2, IL-4, IL-6, CXCL 8. IL-10, IL-16, CXCL10, CCL2, CCL8, CCL7, CCL13, CCL22, MIF, CXCL9, CCL3, CCL15, CCL20, CCL19, CCL23, CXCL16, CXCL12, CCL25, CCL17, TNFa.

[0081] Example 2 Analysis of the diagnostic value of latent infection and active tuberculosis molecular markers and compositions

[0082] To further analyze the diagnostic value of these cytokines or chemokines, we first performed a receiver operating characteristic (ROC) analysis. The area under the ROC curve (AUCs) was used to evaluate the ability of a single chemokine to discriminate between the two groups. Larger AUCs indicate better diagnostic efficacy for that chemokine.

[0083] 2.1 Analysis of the differential diagnostic value of MCP-2 / CCL8

[0084] The AUC of chemokine MCP-2 / CCL8 for differential diagnosis of latent infection and active tuberculosis was 0.890 (see Figure 2 ), with a diagnostic sensitivity of 80.95% and a specificity of 85.00%;

[0085] 2.2 Analysis of the differential diagnostic value of MIG / CXCL9

[0086] The AUC of chemokine MIG / CXCL9 for differential diagnosis of latent infection and active tuberculosis was 0.883 (see Figure 3 ), with a diagnostic sensitivity of 95.24% and a specificity of 65.00%;

[0087] 2.3 Analysis of the differential diagnostic value of MIP-3β / CCL19

[0088] The AUC of the chemokine MIP-3β / CCL19 for differential diagnosis of latent infection and active tuberculosis was 0.864 (see Figure 4 ), with a diagnostic sensitivity of 76.19% and a specificity of 85.00%.

[0089] 2.4 Analysis of the differential diagnostic value of MCP-2 / CCL8 and MIG / CXCL9 combinations

[0090] The AUC of the chemokine combination of MCP-2 / CCL8 and MIG / CXCL9 for identifying tuberculosis infection was calculated using a logistic stepwise regression model and was 0.929 (see Figure 5 ). The overall diagnostic sensitivity was 76.19% and the specificity was 100.00%, both of which had high diagnostic efficacy.

[0091] Chemokines differentially expressed in cell culture plasma between healthy controls and tuberculosis patients were screened. The screened chemokines were used as diagnostic markers and detected using liquid microarray technology. These chemokines can be used for rapid detection of latent infection and active tuberculosis, with high diagnostic efficacy and relatively simple operation, and can improve the detection rate of active tuberculosis (see Table 1).

[0092] Table 1: Analysis of the diagnostic value of chemokines

Claims

1. A biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis, wherein the marker is one or more of CCL8, CXCL9 and CCL19. When the expression level of one or more of CCL8, CXCL9 and CCL19 is higher than the critical value of the factor, the patient can be diagnosed as having active tuberculosis; when the expression level of one or more of CCL8, CXCL9 and CCL19 is lower than or equal to the critical value of the factor, the patient can be diagnosed as having latent tuberculosis infection.

2. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 1, characterized in that: The critical values ​​(pg / mL) of the expression levels of CCL8, CXCL9 and CCL19 are 397.46, 1361.44 and 287.07, respectively.

3. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 1, characterized in that: Tuberculosis is an infectious disease caused by the presence of the pathogen Mycobacterium tuberculosis.

4. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 3, characterized in that: The Mycobacterium tuberculosis infection includes: primary infection, secondary infection, and extrapulmonary infection.

5. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 1, characterized in that: The tuberculosis includes but is not limited to drug-resistant tuberculosis, non-drug-resistant tuberculosis, pulmonary tuberculosis, extrapulmonary tuberculosis, etc.

6. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 5, characterized in that: The drug-resistant tuberculosis includes but is not limited to mono-drug-resistant tuberculosis, multi-drug-resistant tuberculosis, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis.

7. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 5, characterized in that: The pulmonary tuberculosis includes primary pulmonary tuberculosis, secondary pulmonary tuberculosis, blood type disseminated pulmonary tuberculosis, tracheobronchial tuberculosis, tuberculous pleurisy, septic tuberculosis and the like.

8. The biomarker for differential diagnosis of latent tuberculosis infection and active tuberculosis according to claim 5, characterized in that: The extrapulmonary tuberculosis includes but is not limited to intestinal tuberculosis, renal tuberculosis, bone and joint tuberculosis, etc.

9. A kit for differential diagnosis of latent tuberculosis infection and active tuberculosis, the kit containing reagents for detecting biomarkers, instructions, etc., wherein the markers are one or more of CCL8, CXCL9, and CCL19. When the expression levels of one or more of CCL8, CXCL9, and CCL19 are respectively higher than the critical value of the factor, the patient can be diagnosed as a patient with active tuberculosis; when the expression levels of one or more of CCL8, CXCL9, and CCL19 are respectively lower than or equal to the critical value of the factor, the patient can be diagnosed as having latent tuberculosis infection.

10. Use of a biomarker in the preparation of a preparation for differential diagnosis of latent tuberculosis infection and active tuberculosis, wherein the biomarker is one or more of CCL8, CXCL9 and CCL19. When the expression level of one or more of CCL8, CXCL9 and CCL19 is higher than the critical value of the factor, the patient can be diagnosed as having active tuberculosis; when the expression level of one or more of CCL8, CXCL9 and CCL19 is lower than or equal to the critical value of the factor, the patient can be diagnosed as having latent tuberculosis infection.

Citation Information

Patent Citations

  • biomarkers

    CN113748342A

  • Biomarkers for diagnosing and / or monitoring tuberculosis

    US20150192593A1

  • CCL8 based immunological monitoring

    WO2008052566A1

Cited By

  • Biomarker for diagnosing short-term and long-term tuberculosis infection

    CN119780441A

  • Biomarker composition for diagnosing tuberculosis

    CN120099162A